Insecurity of detector-device-independent quantum key distribution

Detector-device-independent quantum key distribution (ddiQKD) held the promise of being robust to detector side-channels, a major security loophole in QKD implementations. In contrast to what has been claimed, however, we demonstrate that the security of ddiQKD is not based on post-selected entanglement, and we introduce various eavesdropping strategies that show that ddiQKD is in fact insecure against detector side-channel attacks as well as against other attacks that exploit device's imperfections of the receiver. Our attacks are valid even when the QKD apparatuses are built by the legitimate users of the system themselves, and thus free of malicious modifications, which is a key assumption in ddiQKD.Comment: 7 pages, 5 figures, 1 tabl

Experimental quantum key distribution with source flaws

Decoy-state quantum key distribution (QKD) is a standard technique in current quantum cryptographic implementations. Unfortunately, existing experiments have two important drawbacks: the state preparation is assumed to be perfect without errors and the employed security proofs do not fully consider the finite-key effects for general attacks. These two drawbacks mean that existing experiments are not guaranteed to be secure in practice. Here, we perform an experiment that for the first time shows secure QKD with imperfect state preparations over long distances and achieves rigorous finite-key security bounds for decoy-state QKD against coherent attacks in the universally composable framework. We quantify the source flaws experimentally and demonstrate a QKD implementation that is tolerant to channel loss despite the source flaws. Our implementation considers more real-world problems than most previous experiments and our theory can be applied to general QKD systems. These features constitute a step towards secure QKD with imperfect devices.Comment: 12 pages, 4 figures, updated experiment and theor

DiskANN++: Efficient Page-based Search over Isomorphic Mapped Graph Index using Query-sensitivity Entry Vertex

Given a vector dataset $\mathcal{X}$ and a query vector $\vec{x}_q$, graph-based Approximate Nearest Neighbor Search (ANNS) aims to build a graph index $G$ and approximately return vectors with minimum distances to $\vec{x}_q$ by searching over $G$. The main drawback of graph-based ANNS is that a graph index would be too large to fit into the memory especially for a large-scale $\mathcal{X}$. To solve this, a Product Quantization (PQ)-based hybrid method called DiskANN is proposed to store a low-dimensional PQ index in memory and retain a graph index in SSD, thus reducing memory overhead while ensuring a high search accuracy. However, it suffers from two I/O issues that significantly affect the overall efficiency: (1) long routing path from an entry vertex to the query's neighborhood that results in large number of I/O requests and (2) redundant I/O requests during the routing process. We propose an optimized DiskANN++ to overcome above issues. Specifically, for the first issue, we present a query-sensitive entry vertex selection strategy to replace DiskANN's static graph-central entry vertex by a dynamically determined entry vertex that is close to the query. For the second I/O issue, we present an isomorphic mapping on DiskANN's graph index to optimize the SSD layout and propose an asynchronously optimized Pagesearch based on the optimized SSD layout as an alternative to DiskANN's beamsearch. Comprehensive experimental studies on eight real-world datasets demonstrate our DiskANN++'s superiority on efficiency. We achieve a notable 1.5 X to 2.2 X improvement on QPS compared to DiskANN, given the same accuracy constraint.Comment: 15 pages including reference

Cytotoxicity Study of Cyclopentapeptide Analogues of Marine Natural Product Galaxamide towards Human Breast Cancer Cells

Herein, we report the cytotoxicity of cyclopentapeptide analogues of marine natural product galaxamide towards breast carcinoma cells and the underlying mechanisms. We examined the effect of the novel galaxamide analogues on cancer cell proliferation by MTT assay and also further examined the most active compound for morphological changes using Hoechst33342 staining technique, induction of apoptosis, cell cycle phases, mitochondrial membrane potential (MMP), and reactive oxygen species (ROS) generation using flow cytometry in human breast cancer MCF-7 cells in vitro. Galaxamide and its analogues effectively induced toxicity in human hepatocellular carcinoma HepG2, human breast carcinoma MCF-7, human epitheloid cervix carcinoma HeLa, and human breast carcinoma MB-MDA-231 cell lines. Amongst them, compound 3 exhibited excellent toxicity towards MCF-7 cells. This galaxamide analogue significantly induced apoptosis in a dose-dependent manner in MCF-7 cells involves cell cycle arrest in the G1 phase, a reduction of MMP, and a marked increase in generation of ROS. Particularly, compound 3 of galaxamide analogues might be a potential candidate for the treatment of breast cancer

Insect-Specific microRNA Involved in the Development of the Silkworm Bombyx mori

MicroRNAs (miRNAs) are endogenous non-coding genes that participate in post-transcription regulation by either degrading mRNA or blocking its translation. It is considered to be very important in regulating insect development and metamorphosis. We conducted a large-scale screening for miRNA genes in the silkworm Bombyx mori using sequence-by-synthesis (SBS) deep sequencing of mixed RNAs from egg, larval, pupal, and adult stages. Of 2,227,930 SBS tags, 1,144,485 ranged from 17 to 25 nt, corresponding to 256,604 unique tags. Among these non-redundant tags, 95,184 were matched to the silkworm genome. We identified 3,750 miRNA candidate genes using a computational pipeline combining RNAfold and TripletSVM algorithms. We confirmed 354 miRNA genes using miRNA microarrays and then performed expression profile analysis on these miRNAs for all developmental stages. While 106 miRNAs were expressed in all stages, 248 miRNAs were egg- and pupa-specific, suggesting that insect miRNAs play a significant role in embryogenesis and metamorphosis. We selected eight miRNAs for quantitative RT-PCR analysis; six of these were consistent with our microarray results. In addition, we searched for orthologous miRNA genes in mammals, a nematode, and other insects and found that most silkworm miRNAs are conserved in insects, whereas only a small number of silkworm miRNAs has orthologs in mammals and the nematode. These results suggest that there are many miRNAs unique to insects

Methylprednisolone as Adjunct to Endovascular Thrombectomy for Large-Vessel Occlusion Stroke

Importance It is uncertain whether intravenous methylprednisolone improves outcomes for patients with acute ischemic stroke due to large-vessel occlusion (LVO) undergoing endovascular thrombectomy. Objective To assess the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for acute ischemic stroke secondary to LVO. Design, Setting, and Participants This investigator-initiated, randomized, double-blind, placebo-controlled trial was implemented at 82 hospitals in China, enrolling 1680 patients with stroke and proximal intracranial LVO presenting within 24 hours of time last known to be well. Recruitment took place between February 9, 2022, and June 30, 2023, with a final follow-up on September 30, 2023.InterventionsEligible patients were randomly assigned to intravenous methylprednisolone (n = 839) at 2 mg/kg/d or placebo (n = 841) for 3 days adjunctive to endovascular thrombectomy. Main Outcomes and Measures The primary efficacy outcome was disability level at 90 days as measured by the overall distribution of the modified Rankin Scale scores (range, 0 [no symptoms] to 6 [death]). The primary safety outcomes included mortality at 90 days and the incidence of symptomatic intracranial hemorrhage within 48 hours. Results Among 1680 patients randomized (median age, 69 years; 727 female [43.3%]), 1673 (99.6%) completed the trial. The median 90-day modified Rankin Scale score was 3 (IQR, 1-5) in the methylprednisolone group vs 3 (IQR, 1-6) in the placebo group (adjusted generalized odds ratio for a lower level of disability, 1.10 [95% CI, 0.96-1.25]; P = .17). In the methylprednisolone group, there was a lower mortality rate (23.2% vs 28.5%; adjusted risk ratio, 0.84 [95% CI, 0.71-0.98]; P = .03) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%; adjusted risk ratio, 0.74 [95% CI, 0.55-0.99]; P = .04) compared with placebo. Conclusions and Relevance Among patients with acute ischemic stroke due to LVO undergoing endovascular thrombectomy, adjunctive methylprednisolone added to endovascular thrombectomy did not significantly improve the degree of overall disability.Trial RegistrationChiCTR.org.cn Identifier: ChiCTR210005172